GlucoMen iCan

CGM Device Guide – Coming Soon

GlucoMen iCan

GlucoMen iCan has a promising clinical trial MARD of 8.71% and is expected to move towards full framework inclusion. Before it gets there, there are two things that need to be understood – the gap between trial and real-world performance, and the current UK regulatory status.

CGM Coming soon

Read this first – current UK status

As of April 2026, GlucoMen iCan is approved for adjunctive use only in the UK. This means it cannot be used as the sole basis for an insulin dosing decision without a confirmatory finger prick blood glucose test. This is a significant regulatory distinction that applies regardless of the MARD figure.

This page will be updated when non-adjunctive UK status is confirmed and when published accuracy data meets the DSNFUK framework threshold.

Current status

Framework criteriaPending
Data sufficiency thresholdPending full published evidence
UK regulatory statusAdjunctive only – insulin dosing decisions require confirmatory finger prick
CE markingYes – age 2 and older
Published MARD (pivotal trial)8.71% (Diabetes Technology and Therapeutics, 2024)
Published MARD (real-world study)17.2% – significantly higher than trial data
Wear duration15 days
AID compatibleNot confirmed
UK distributorMenarini Diagnostics Ltd (Wokingham)
ManufacturerSinoCare (China)

The trial vs real-world gap

The pivotal clinical trial for GlucoMen iCan reports a MARD of 8.71% – which, if accurate and generalisable, would place it among the most accurate CGMs currently available. That would be a significant result for a 15-day sensor.

A published real-world study, however, reports a MARD of 17.2%. That is almost double the trial figure. A MARD of 17.2% means that on average across real-world use, the sensor is nearly 17% away from a blood glucose reference – a level of inaccuracy that creates meaningful risk for insulin dosing decisions.

This discrepancy requires explanation before full clinical confidence can be placed in the device. Common causes of trial-to-real-world gaps in CGM accuracy include:

  • Controlled clinic conditions in trial vs. real-world movement, temperature variation, and skin perfusion
  • Highly trained participants in trial vs. general population device use
  • Study design differences in reference glucose methods
  • Early-generation device performance improving in later real-world batches (or the reverse)

Until this gap is understood and addressed in published data, the real-world figure is the clinically relevant number for most patients.

Why it is on this page at all

GlucoMen iCan is included here because the off-the-record data from ATTD 2026 indicates it is moving towards published accuracy data that may meet the DSNFUK 5/5 framework threshold. When that evidence is published and the real-world picture is clearer, it will be assessed for full inclusion.

It is included as a placeholder so that patients and HCPs encountering the device can find context, not just a gap. The most important clinical messages right now are: adjunctive only, and the real-world MARD is substantially different from the trial figure.

When this page will be updated

This page will be upgraded when two conditions are met: the UK regulatory status moves to non-adjunctive, and published accuracy data meets the DSNFUK sufficiency threshold in a way that addresses the trial-to-real-world gap. We are in contact with Menarini Diagnostics on both points.

Menarini Diagnostics UK contact: Christian Walker – cwalker@menarinidiag.com